Silvia Noiman
Chief Executive Officer at Imel Biotherapeutics, Inc.
Profile
Silvia Noiman is the founder.
She founded Predix Pharmaceuticals Holdings, Inc. in 2000, cCAM Biotherapeutics Ltd.
in 2010, Eloxx Pharmaceuticals Ltd.
in 2013, and Eloxx Pharmaceuticals, Inc. in 2017.
At Predix Pharmaceuticals Holdings, Inc., she held the title of Senior Vice President.
At cCAM Biotherapeutics Ltd., she was the Executive Chairman from 2010 to 2015.
At Eloxx Pharmaceuticals Ltd., she served as the Chief Executive Officer & Director from 2013 to 2017.
At Eloxx Pharmaceuticals, Inc., she was a Director from 2017 to 2021.
Dr. Noiman is also the founder of Predix Pharmaceuticals Ltd.
Dr. Noiman's current job(s) include being the Chairman & Chief Executive Officer at Imel Biotherapeutics, Inc. and a Director at Vico Therapeutics BV since 2020.
Her former job(s) include being the Executive Chairman at Quiet Therapeutics Ltd.
from 2010 to 2015 and a Venture Partner at Pontifax Management Co. Ltd.Dr. Noiman obtained a doctorate degree from Tel-Aviv University.
Silvia Noiman active positions
Companies | Position | Start |
---|---|---|
Vico Therapeutics BV
Vico Therapeutics BV BiotechnologyHealth Technology Vico Therapeutics BV is a private biotech company based in Leiden, Netherlands that focuses on developing RNA modulating therapies for rare severe neurological disorders. The Dutch company's antisense oligonucleotide platform (AON) is directed towards different forms of spinocerebellar ataxia (SCA) and Huntington disease (HD), while its early discovery RNA editing platform is directed towards Rett syndrome. Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Gail Mandel, and Dr. Judith van Deutekom, who have strong academic reputations and vast industry experience. Micah Mackison has been the CEO of the company since 2022. | Director/Board Member | 2020-07-28 |
Imel Biotherapeutics, Inc.
Imel Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Imel Biotherapeutics, Inc. develops treatment for mitochondrial disease. The company was founded on February 21, 2019 and is headquartered in United States. | Chief Executive Officer | - |
Former positions of Silvia Noiman
Companies | Position | End |
---|---|---|
ELOXX PHARMACEUTICALS, INC. | Founder | 2021-03-31 |
cCAM Biotherapeutics Ltd.
cCAM Biotherapeutics Ltd. Pharmaceuticals: MajorHealth Technology cCAM Biotherapeutics Ltd. is a preclinical-stage company engaging in the development of immunotherapies to treat cancer. The company was founded by Silvia Noiman and Gal Markel in 2010 and is headquartered in Hod Ha'Sharon, Israel. | Founder | 2015-06-30 |
Predix Pharmaceuticals Holdings, Inc.
Predix Pharmaceuticals Holdings, Inc. Pharmaceuticals: MajorHealth Technology Predix Pharmaceuticals Holdings, Inc. is a pharmaceutical company focused on the discovery and development of novel, highly selective, small-molecule drugs that target G-Protein Coupled Receptors (GPCRs) and ion channels. | Founder | - |
Pontifax Management Co. Ltd.
Pontifax Management Co. Ltd. Investment ManagersFinance Pontifax Management Co. Ltd. (Pontifax) is a venture capital firm founded in 2004 by Eliyahu Hurvitz. The firm is headquartered in Herzliya Pituach, Israel. | Private Equity Investor | - |
Quiet Therapeutics Ltd.
Quiet Therapeutics Ltd. Medical SpecialtiesHealth Technology Quiet Therapeutics Ltd. develops a proprietary nanoparticle-based delivery system for the targeted delivery of chemotherapy and anti-inflammatory drugs. It developed a class of cancer therapeutics called GAGomers, enables the flexibility of delivering a medicine that can kill the cancer cells and block the production of proteins that promote the cancer. The company was founded by Dan Peer and Rimona Margalit in 2009 and is headquartered in Ness Ziona, Israel. | Chairman | 2015-06-30 |
Training of Silvia Noiman
Tel-Aviv University | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
ELOXX PHARMACEUTICALS, INC. | Health Technology |
Private companies | 8 |
---|---|
Predix Pharmaceuticals Holdings, Inc.
Predix Pharmaceuticals Holdings, Inc. Pharmaceuticals: MajorHealth Technology Predix Pharmaceuticals Holdings, Inc. is a pharmaceutical company focused on the discovery and development of novel, highly selective, small-molecule drugs that target G-Protein Coupled Receptors (GPCRs) and ion channels. | Health Technology |
Predix Pharmaceuticals Ltd. | |
Pontifax Management Co. Ltd.
Pontifax Management Co. Ltd. Investment ManagersFinance Pontifax Management Co. Ltd. (Pontifax) is a venture capital firm founded in 2004 by Eliyahu Hurvitz. The firm is headquartered in Herzliya Pituach, Israel. | Finance |
cCAM Biotherapeutics Ltd.
cCAM Biotherapeutics Ltd. Pharmaceuticals: MajorHealth Technology cCAM Biotherapeutics Ltd. is a preclinical-stage company engaging in the development of immunotherapies to treat cancer. The company was founded by Silvia Noiman and Gal Markel in 2010 and is headquartered in Hod Ha'Sharon, Israel. | Health Technology |
Quiet Therapeutics Ltd.
Quiet Therapeutics Ltd. Medical SpecialtiesHealth Technology Quiet Therapeutics Ltd. develops a proprietary nanoparticle-based delivery system for the targeted delivery of chemotherapy and anti-inflammatory drugs. It developed a class of cancer therapeutics called GAGomers, enables the flexibility of delivering a medicine that can kill the cancer cells and block the production of proteins that promote the cancer. The company was founded by Dan Peer and Rimona Margalit in 2009 and is headquartered in Ness Ziona, Israel. | Health Technology |
Eloxx Pharmaceuticals Ltd.
Eloxx Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Eloxx Pharmaceuticals Ltd. provides biopharmaceutical research and development services. The firm specializes in the discovery, development, and commercialization of drug compounds for the treatment of genetic diseases. It focuses on the treatment of diseases caused by nonsense mutations, including Cystic fibrosis, Duchene Muscular Dystrophy, Usher syndrome, Ataxia-telangiectasia, Beta thalassemia, and Tay-Sachs Hurler syndrome. Its focus areas encompass clinical drug development and target drugs discovery programs. The company was founded by Silvia Noiman and Shmuel Tuvia in 2013 and is headquartered in Herzliya, Israel. | Health Technology |
Vico Therapeutics BV
Vico Therapeutics BV BiotechnologyHealth Technology Vico Therapeutics BV is a private biotech company based in Leiden, Netherlands that focuses on developing RNA modulating therapies for rare severe neurological disorders. The Dutch company's antisense oligonucleotide platform (AON) is directed towards different forms of spinocerebellar ataxia (SCA) and Huntington disease (HD), while its early discovery RNA editing platform is directed towards Rett syndrome. Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Gail Mandel, and Dr. Judith van Deutekom, who have strong academic reputations and vast industry experience. Micah Mackison has been the CEO of the company since 2022. | Health Technology |
Imel Biotherapeutics, Inc.
Imel Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Imel Biotherapeutics, Inc. develops treatment for mitochondrial disease. The company was founded on February 21, 2019 and is headquartered in United States. | Commercial Services |
- Stock Market
- Insiders
- Silvia Noiman